Oligohydramnios affects pulmonary functional/ structural abnormalities in school-aged children with bronchopulmonary dysplasia

Jeong Eun Shin, MD, PhD¹, Soon Min Lee, MD, PhD², Mi-Jung Lee, MD, PhD³, Jungho Han, MD¹, Joohee Lim, MD, PhD², Haerin Jang, MSc¹, Ho Seon Eun, MD¹, Min Soo Park, MD, PhD¹, Soo Yeon Kim, MD¹, Myung Hyun Sohn, MD, PhD¹, Ji Ye Jung, MD, PhD⁴, Kyung Won Kim, MD, PhD^{1,5}

¹Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea; ²Department of Pediatrics, Gangnam Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea; ³Department of Radiology, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea; ⁴Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea; ⁵Institute for Innovation in Digital Healthcare, Yonsei University, Seoul, Korea

Background: The relationship between early life factors and childhood pulmonary function and structure in preterm infants remains unclear.

Purpose: This study investigated the impact of bronchopulmonary dysplasia (BPD) and perinatal factors on childhood pulmonary function and structure.

Methods: This longitudinal cohort study included preterm participants aged ≥ 5 years born between 2005 and 2015. The children were grouped by BPD severity according to National Institutes of Health criteria. Pulmonary function tests (PFTs) were performed using spirometry. Chest computed tomography (CT) scans were obtained and scored for hyperaeration or parenchymal lesions. PFT results and chest CT scores were analyzed with perinatal factors.

Results: A total 150 children (66 females) aged 7.7 years (6.4–9.9 years) were categorized into non/mild BPD (n=68), moderate BPD (n=39), and severe BPD (n=43) groups. The median *z* score for forced expiratory volume in 1 second (FEV₁), forced vital capacity (FVC), FEV₁/FVC ratio, and forced midexpiratory flow (FEF_{25%-75%}) were significantly lower in the severe versus non/mild BPD group (-1.24 vs. -0.18, -0.22 vs. 0.41, -1.80 vs. -1.12, and -1.88 vs. -1.00, respectively; all *P*<0.05). The median *z* scores of FEV₁, FEV₁/FVC, and FEF_{25%-75%} among asymptomatic patients were also significantly lower in the severe versus non/mild BPD group (-0.82 vs. 0.09, -1.68 vs. -0.87, -1.59 vs. -0.61, respectively; all *P*<0.05). The severe BPD group had a higher median (range) CT score than the non/mild BPD group (6 [0–12] vs. 1 [0–10], *P*<0.001). Prenatal oligohydramnios was

strongly associated with both low pulmonary function (FEV₁/FVC<lower limit of normal; odds ratio, 3.54) and high CT score (median difference, 2.54).

Conclusion: School-aged children with severe BPD showed airflow limitations and structural abnormalities despite no subjective respiratory symptoms. These results suggest that patients with a history of prenatal oligohydramnios or prolonged mechanical ventilation require extended follow-up.

Key words: Prematurity, Bronchopulmonary dysplasia, Respiratory function test, Cohort study, Oligohydramnios

Key message

Question: Is bronchopulmonary dysplasia (BPD) associated with functional/structural abnormalities later in life?

- **Finding:** School-aged children with severe BPD had abnormalities on pulmonary function tests and lung computed tomography despite no subjective respiratory symptoms; however, only prenatal oligohydramnios and prolonged ventilator use were associated with abnormal lung function.
- **Meaning:** Long-term monitoring of preterm infants' lung health is essential, especially for those with prenatal oligohydramnios or prolonged ventilator use.

Introduction

Preterm birth rates have increased globally, and according to a recent estimate, preterm births account for 10.6% of


Corresponding Author: Kyung Won Kim, MD, PhD. Department of Pediatrics, Yonsei University College of Medicine, 50-1 Yonsei-Ro, Seodaemun-gu, Seoul 03722, Korea 🖾 Email: kwkim@yuhs.ac, https://orcid.org/0000-0003-4529-6135

Co-corresponding Author: Ji Ye Jung, MD, PhD. Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-Ro, Seodaemun-gu, Seoul 03722, Korea

Email: stopyes@yuhs.ac, https://orcid.org/0000-0003-1589-4142

Received: 20 September, 2023, Revised: 9 December 2023, Accepted: 1 February 2024

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © 2024 by The Korean Pediatric Society



Graphical abstract. BPD, bronch-opulmonary dysplasia; CT, computed tomography.

live births.¹⁾ In Korea, the survival rate of infants with very low birth weight more than doubled, increasing from 38.3% in the 1980s to 84.8% in 2014, while that of infants with extremely low birth weight increased more than fivefold, from 12.3% in the 1980s to 69.6% in 2014.²⁾ Therefore, there is a growing emphasis on the healthy growth of preterm infants beyond their survival.

Lung volume and function reach the maximum values in the late 20s and, then decline steadily with age. However, in patients who experienced an early lung injury or maldevelopment during infancy, respiratory symptoms may appear earlier, which can lead to reduced peak lung growth.³⁾ Several cohorts of patients with preterm lung growth have been established to track the respiratory functions of prematurity survivors. Impaired pulmonary function, predominantly obstructive patterns, or structural alteration of the lungs have been reported in cohorts of very preterm- or extremely preterm-born children aged 5–11 years in the US, UK, Australia, and Italy.⁴⁻⁸⁾

Our recent study, using large-scale nationwide claims data, revealed that bronchopulmonary dysplasia (BPD) is associated with high respiratory morbidity in terms of rehospitalization rates, intensive care rates, and childhood asthma prevalence in recent survivors with respiratory distress syndrome (RDS).⁹⁾ However, considering the nature of the claims data, it was difficult to accurately determine the effects of prematurity and BPD associated with respiratory morbidity. Therefore, the impact of BPD on pulmonary functional and structural changes in school-aged preterm-born, surfactant-treated individuals needed to be investigated. In this context, we established the LONGitudinal cohort study of the population born preTERM (LONGTERM) to investigate

serial lung development in preterm-born children from preschool age to adulthood; to the best of our knowledge, this is the first such study in Korea. In this interim data analysis from the LONGTERM cohort, we reported the functional and structural statuses of the participants. We also investigated whether BPD and other perinatal factors are associated with abnormal function in school-aged preterm-born children.

Methods

1. Participants

Children aged ≥5 years who were born prematurely, admitted to the Severance or Gangnam Severance Hospital neonatal intensive care units (NICU), and treated with pulmonary surfactants owing to RDS between 2005 and 2015 were recruited into the LONGTERM cohort. Patients who died, had congenital cardiopulmonary anomalies or neurologic impairments that made it challenging to perform pulmonary function tests (PFTs), or whose personal information could not be obtained were excluded. Among the preterm-born children with RDS (N=1,207), 57.8% (N=700) were eligible for enrollment in the LONGTERM cohort. We contacted 353 patients between November 2019 and August 2021, of whom 150 (48.1%) completed their visits; these patients' data were analyzed (Supplementary Fig. 1). The participants were then classified into 3 groups: non/mild, moderate, and severe BPD. This study was conducted in accordance with the principles of the Declaration of Helsinki. All participants and their parents were fully informed of the purpose and procedures of the study, and the parents

provided their written informed consent before enrollment. The Institutional Review Board (IRB) of Severance Hospital (IRB No. 4-2019-0914) and Gangnam Severance hospital (IRB No. 3-2020-0195) reviewed and approved the study protocol.

2. Study design

Maternal and neonatal data were collected from the medical records of each hospital. Prior and current respiratory health status, environmental exposures, parental history of allergic diseases, and socioeconomic status data were obtained through questionnaires that were answered by parents. All participants underwent PFTs. Chest computed tomography (CT) and laboratory studies were performed after obtaining additional consent from the parents and children.

3. Definition of BPD

BPD was defined as at least 28 days of supplemental oxygen requirement and was graded as mild, moderate, or severe, according to the definitions of National Institutes of Health criteria proposed by Jobe and Bancalari¹⁰⁾ More specifically, the severity of BPD was graded according to the respiratory support at 36 weeks postmenstrual age: mild BPD if room air was sufficient, moderate BPD if <30% oxygen was required, severe BPD if \geq 30% oxygen or positive pressure was required.

4. Demographics

Maternal and neonatal data; gestational age, birth weight, sex, small for gestational age, delivery mode, twin birth, antenatal/postnatal steroid use, maternal risk factors (pregnancy-induced hypertension, chorioamnionitis, oligohydramnios, premature rupture of membrane), use of surfactant, the duration and mode of respiratory support, and comorbidities were collected from medical records. The height and weight of the patients were measured at the time of the visit for the PFT.

5. Asymptomatic patients

Based on medical records and questionnaire, participants were classified as "asymptomatic" when they fulfilled the following requirements: (1) no regular respiratory check-ups; (2) absence of subjective respiratory symptoms (e.g., cough, sputum, and dyspnea); and (3) no significant lower respiratory tract infections (LRIs) in the past year. Significant LRI was defined as an infection requiring medication for >1 week or hospital admission within the past 1 year.

6. Pulmonary function test

All tests were performed per the American Thoracic Society guidelines.¹¹⁾ Forced expiratory volume in 1 second

(FEV₁), forced vital capacity (FVC), FEV₁/FVC ratio, and forced midexpiratory flow (FEF_{25%-75%}) were measured before and after inhalation of a bronchodilator. All parameters were calibrated according to age, sex, height, weight, and ethnicity.¹²⁾ Estimates were obtained using the reference values of the Global Lung Function Institute (GLI).¹³⁾ A *z* score \leq -1.64 was considered below the lower limit of normal (LLN). Bronchodilator response (BDR) was considered positive compared with baseline data when FEV₁ increased by \geq 12% after inhaling salbutamol compared with baseline data.

7. Chest CT

A pediatric radiologist with 18 years of experience in pediatric chest CT performed the semiguantitative assessment of disease severity using CT images. We modified a previously reported scoring system based on lobes rather than lung segments.¹⁴⁾ The presence (score 1) or absence (score 0) of lung lesions, including 2 categories of hyperaeration and parenchymal lesions, was evaluated for each lung lobe. The left lingular segment was considered one lobe. The hyperaeration score (range, 0-6) referred to the number of lobes showing areas of reduced lung attenuation, mosaic attenuation pattern, or bullas/blebs. The parenchymal lesion score (range, 0-6) referred to the number of lobes with linear lesions, segmental atelectasis, consolidation, or architectural distortion. The sum of these 2 scores was used as the CT severity score assigned to each patient. CT severity was compared based on the severity of BPD (non/mild, moderate, or severe BPD) and PFT results (below the LLN or above the LLN for each parameter).

8. Laboratory studies

General health information, including leukocyte counts with differential; platelet counts; and hemoglobin, aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen, creatinine, and C-reactive protein level measurements, was obtained for each participant from their laboratory studies. Total serum immunoglobulin E (IgE) levels were measured using the ImmunoCAP assay (Thermo Fisher Scientific, Uppsala, Sweden), and specific IgE levels were measured using a multiple antigen simultaneous test immunoblot assay for 61 inhalants (AdvanSure Alloscreen; LG Life Science, Seoul, Korea). Atopy was defined as a specific IgE level of ≥ 2 against >1 allergen or a total IgE level of 150 IU/mL.

9. Statistical analysis

Data were analyzed using R (ver. 4.1.1; R Foundation for Statistical Computing, Vienna, Austria) and IBM SPSS Statistics ver. 24.0 (IBM Co., Armonk, NY, USA). Categorical variables are presented as frequency (%) for each group

and continuous variables are presented as the median

with interquartile range (IQR). PFT and CT score data are presented as median (ranges). The values were compared

among the 3 BPD groups using Fisher exact test for the

categorical variables and the Kruskal-Wallis test, followed

by Bonferroni post hoc analysis for the continuous variables.

The 2-sample t test was used to compare values between the

groups with PFT results below or above the LLN. The values

of asymptomatic and symptomatic patients were compared

using the Mann-Whitney U test for the continuous vari-

ables and Fisher exact test for the categorical variables. Uni-

variate and multivariate logistic regression analyses were

used to analyze the influence of independent perinatal risk

factors on PFT results. Univariate and multivariate quantile

(median) regression analyses were used to assess the influ-

ence of independent perinatal factors on chest CT scores.

Variables that showed statistical significance in the univa-

riate analysis were selected as covariates for the multivariate

regression. Statistical significance was set at P<0.05.

Table 1. Participants' perinatal/neonatal characteristics

Results

1. Participant demographics

The median (IOR) gestational age was 28.8 weeks (27.2-30.1 weeks); 51 participants (34.0%) were born at a gestational age ≤ 27 weeks. The median birth weight was 1.145 g (range, 910-1,423 g), and 53 (35.3%) and 65 participants (43.3%) had birth weights of <1,000 g and 1,000-1,500 g, respectively. Non/mild, moderate, and severe cases of BPD were observed in 68 (45.3%), 39 (26.0%), and 43 patients (28.7%), respectively. Participants' clinical characteristics at the time of NICU discharge are summarized in Table 1. The severe BPD group had significantly lower gestational age and birth weight and higher rates of maternal chorioamnionitis than the moderate and non/mild BPD groups. Moreover, the median durations of respiratory support and mechanical ventilation were 2.5 and 4.5 times longer in the severe BPD group than in the non/mild groups, respectively (Table 1).

Supplementary Table 1 summarizes participants' clinical characteristics at the time of the visit. The median (IOR)

Boldface indicates a statistically significant difference with P<0.05.

| Variable - | BPD group | | | | | |
|---|--------------------|------------------|-------------------|----------------------------------|--|--|
| | Non/mild (N=68) | Moderate (N=39) | Severe (N=43) | P value | | |
| GA (wk) | 29.9 (28.9–30.9) | 28.0 (26.6–28.9) | 27.2 (26.1–28.9) | <0.001 ^{b,c)} | | |
| Birth weight (g) | 1,388 (1,200–1631) | 998 (852–1,190) | 940 (773–1,080) | <0.001 ^{b,c)} | | |
| Female sex | 24 (35.3) | 17 (43.6) | 25 (58.1) | 0.061 | | |
| SGA | 6 (8.8) | 8 (20.5) | 7 (16.3) | 0.215 | | |
| C-sec | 49 (72.1) | 32 (82.1) | 29 (67.4) | 0.311 | | |
| Twin birth | 27 (39.7) | 15 (38.5) | 14 (32.6) | 0.739 | | |
| Antenatal steroid treatment | 26 (38.2) | 18 (46.2) | 21 (48.8) | 0.434 | | |
| PIH | 11 (16.2) | 11 (28.2) | 8 (18.6) | 0.326 | | |
| Chorioamnionitis | 11 (16.2) | 5 (12.8) | 15 (34.9) | 0.012 ^{b)} | | |
| Oligohydramnios | 6 (8.8) | 4 (10.3) | 5 (11.6) | 0.757 | | |
| PROM | 25 (36.8) | 13 (33.3) | 17 (39.5) | 0.630 | | |
| Surfactant treatment | 68 (100) | 39 (100) | 43 (100) | - | | |
| No. of surfactant treatments | 1 (1–1) | 1 (1–2) | 1 (1–2) | 0.089 | | |
| Use of systemic steroids | 1 (1.5) | 11 (28.2) | 12 (27.9) | <0.001 ^{b)} | | |
| Respiratory support | | | | | | |
| The total duration of respiratory support ^{a)} (day) | 30.3 (14.8-41.3) | 72.0 (60.0–79.0) | 90.0 (74.0-121.0) | <0.001 ^{b,c,d)} | | |
| Duration of NIV (day) | 6.5 (0–15) | 16.5 (0.3–30.0) | 11.0 (4.5–28.0) | 0.019 ^{b)} | | |
| Duration of MV (day) | 9.4 (2–12.3) | 26.0 (14.0-38.0) | 42.0 (19.0-67.0) | < 0.001 ^{b,c,d)} | | |
| Comorbidities | | | | | | |
| PDA-treated | 15 (22.1) | 20 (51.3) | 19 (44.2) | 0.010 ^{c)} | | |
| PDA-surgically treated | 7 (10.3) | 8 (20.5) | 9 (20.9) | 0.014 ^{c)} | | |
| Sepsis | 0 (0) | 0 (0) | 2 (4.7) | 0.088 | | |
| PVL | 2 (2.9) | 1 (2.6) | 4 (9.3) | 0.218 | | |
| IVH | 13 (19.1) | 10 (25.6) | 14 (32.6) | 0.243 | | |
| NEC | 1 (1.5) | 2 (5.1) | 1 (2.3) | 0.532 | | |

Values are presented as median (interquartile range) or number (%).

BPD, bronchopulmonary dysplasia; GA, gestational age; SGA, small for gestational age; C-sec, cesarean section; PIH, pregnancy-induced hypertension; PROM, premature rupture of membranes; NIV, noninvasive ventilation; MV, mechanical ventilation; PDA, patent ductus arteriosus; PVL, periventricular leukomalacia; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis

^{a)}Duration of mechanical ventilation, noninvasive ventilation, and supplemental oxygen. ^{b)}Non/mild BPD vs. severe BPD. ^{d)}Non/mild BPD vs. moderate BPD. ^{d)} Moderate BPD vs. severe BPD

age at the visit was 7.7 years (6.4–9.9 years). Body weight was lower in the severe BPD group than in the moderate and non/mild BPD groups, while height and proportion of asymptomatic patients did not differ among the groups. The rate of significant LRIs was higher in the severe BPD group than in the non/mild BPD group (P=0.045). The frequency of asthma diagnosis was higher in the severe BPD group than in the non/mild BPD group (P<0.001). However, the prevalence of allergic diseases, total IgE levels, presence of atopy, and eosinophil counts did not differ among




Fig. 1. Proportion of patients with pulmonary function below the LLN. The proportion of participants with pulmonary function below the LLN tended to increase as BPD severity increased. The proportion of participants with FEV1/FVC (60.5% vs. 33.8%, *P*=0.02) and FEF25%-75% (53.5% vs. 30.9%, *P*=0.048)<LLN was significantly higher in the severe than non/mild BPD group (**P*<0.05). LLN, lower limit of normal; BPD, bronchopulmonary dysplasia; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; FEF25-75%, forced midexpiratory flow.

the groups. Family history of allergic diseases and environmental factors were also not different.

2. Pulmonary functions according to BPD severity

Among all study participants, the severe BPD group had a significantly higher proportion of patients with FEV₁/ FVC and FEF_{25%-75%} below the LLN than the non/mild BPD group (Fig. 1). FEV₁/FVC was most frequently below the LLN (60.5%) among the pulmonary function parameters in the severe BPD group. PFT results were compared between asymptomatic and symptomatic patients. The z scores of FEV₁, FEV₁/FVC, and FEF_{25%-75%} were significantly lower in symptomatic patients than in asymptomatic patients (-1.25 vs. -0.3, -2.39 vs. -1.18, -2.09 vs. -0.98, all P<0.001, Supplementary Table 2). However, among the asymptomatic patients, 36.1% had FEV₁/FVC below the LLN, and 29.6% had FEF_{25%-75%} below the LLN (Supplementary Table 2). According to the BPD severity in asymptomatic patients, the median z scores of FEV₁, FEV₁/FVC, and FEF_{25-75%} results remained significantly lower in the severe BPD group than in the non/mild BPD group. (-0.82 vs. 0.09, P=0.008; -1.68 vs.-0.87, P=0.038; and -1.59 vs. -0.61, P=0.005, respectively; Table 2). The proportion of patients with FEV_1/FVC and $FEF_{25\%-}$ 75% below the LLN was also significantly higher in the severe BPD group than in the non/mild BPD group (53.3% vs. 25%, P=0.013; and 46.7% vs, 19.2%, P=0.035, respectively; Table 2). In contrast, the proportions of patients with BDR ≥12% did not differ among the groups. The PFT results of all patients are presented in Supplementary Table 3.

3. Pulmonary structures according to BPD severity

Chest CT was performed on 90% of the participants (N=

| Pulmonary function test | Non/mild BPD (n=52) | Moderate BPD (n=26) | Severe BPD (n=30) | P value |
|---|-----------------------|-----------------------|-----------------------|----------------------------|
| FEV1 (%pred) | 102.7 (76.2–130) | 94.3 (66.3–117.2) | 93.0 (61.9–107.4) | 0.003 ^{a)} |
| FEV1 (z score) | 0.09 (-2.03 to 2.93) | -0.41 (-3.56 to 0.89) | -0.82 (-3.39 to 0.38) | 0.008 ^{a)} |
| FEV1 < LLN | 6 (11.5) | 4 (15.4) | 7 (23.3) | 0.368 |
| FVC (%pred) | 100.4 (73.0–129.5) | 98.9 (69.7–115.1) | 94.8 (80.3–113.8) | 0.051 |
| FVC (z score) | 0.68 (-2.12 to 3.96) | 0.60 (-4.07 to 2.31) | -0.29 (-2.07 to 2.30) | 0.052 |
| FVC < LLN | 5 (9.6) | 2 (7.7) | 4 (13.3) | 0.771 |
| FEV1/FVC (%) | 85.5 (66.5–95.6) | 82.7 (64.4-91.2) | 79.6 (58.0-95.3) | 0.024 ^{a)} |
| FEV1/FVC (%pred) | 100.2 (77.7–112.6) | 96.7 (75.6–106.8) | 93.7 (67.6–113.1) | 0.013 ^{a)} |
| FEV1/FVC (z score) | -0.87 (-3.35 to 1.32) | -1.19 (-3.50 to 0.95) | -1.68 (-3.80 to 1.53) | 0.038 ^{a)} |
| FEV1/FVC <lln< td=""><td>13 (25.0)</td><td>10 (38.5)</td><td>16 (53.3)</td><td>0.035^{a)}</td></lln<> | 13 (25.0) | 10 (38.5) | 16 (53.3) | 0.035 ^{a)} |
| FEF25%-75% (%pred) | 72.8 (24.1-88.7) | 70.7 (31.2–103.3) | 64.0 (21.1–106.0) | 0.265 |
| FEF25%-75% (z score) | -0.61 (-3.84 to 1.54) | -1.00 (-3.25 to 0.84) | -1.59 (-3.67 to 0.74) | 0.005 ^{a)} |
| FEF25%-75% <lln< td=""><td>10 (19.2)</td><td>8 (38.5)</td><td>14 (46.7)</td><td>0.035^{a)}</td></lln<> | 10 (19.2) | 8 (38.5) | 14 (46.7) | 0.035 ^{a)} |
| BDR ≥12% | 7 (13.5) | 5 (19.2) | 5 (16.7) | 0.794 |

Table 2. Pulmonary function test results in asymptomatic patients by BPD severity

Values are presented as median (range) or number (%).

BPD, bronchopulmonary dysplasia; FEV1, forced expiratory volume in 1 second; LLN, lower limit of normal; FVC, forced vital capacity; FEF25%-75%, forced mid-expiratory flow; BDR, bronchodilator response.

^{a)}P<0.05, severe vs. non/mild BPD.

Boldface indicates a statistically significant difference with *P*<0.05.

135). Among asymptomatic patients, differences in the median (range) CT scores among non/mild, moderate, and severe BPD groups were significant; (1 [0–10], 2 [0–12], and 5 [0–12], respectively; severe vs. non/mild BPD, P<0.001) (Fig. 2A). In all patients, the median (range) CT scores in the non/mild, moderate, and severe BPD groups were 1 (0–10), 4 (0–12), and 6 (0–12), respectively (severe vs. non/mild BPD, P<0.001) (Fig. 2B). The comparison of CT scores

between the groups with PFT results below and above the LLN yielded the following results: 6 vs. 2, P<0.001 for FEV₁; 6 vs. 3, P=0.059 for FVC; 6 vs. 1, P<0.001 for FEV₁/FVC; and 7 vs. 1, P<0.001 for FEF_{25%-75%} (Fig. 3A–D).

4. Perinatal factors associated with airflow limitation and structural abnormalities

According to the univariate analysis, gestational age, birth




Fig. 2. Chest CT scores by BPD severity. (A) Among asymptomatic patients, the median (range) CT scores of the non/mild (n=49), moderate (n=24), and severe (n=25) BPD groups were 1 (0–10), 2 (0–12), and 5 (0–12), respectively; non/mild versus severe BPD, *P*<0.001. (B) Among all patients, the median (range) CT scores in the severe (n=35), moderate (n=36), and non/mild (n=64) groups were 1 (0–10), 4 (0–12), and 6 (0–12), respectively (non/mild vs. severe BPD, *P*<0.001; non/mild vs. moderate BPD, *P*<0.01). Chest CT studies were performed in 90% of the entire study population (n=98 of 108 asymptomatic patients, n=135 of 150 overall patients). CT, computed tomography; BPD, bronchopulmonary dysplasia; ns, not significant. ***P*<0.001. ****P*<0.001.




Fig. 3. Chest CT scores by PFT results. CT scores of groups with PFT results below versus above the LLN: (A) 6 vs. 2, P<0.001 for FEV1; (B) 6 vs. 3, P=0.059 for FVC; (C) 6 vs. 1, P<0.001 for FEV1/FVC; and (D) 7 vs. 1, P<0.001 for FEF25%-75%. CT, computed tomography; PFT, pulmonary function test; LLN, lower limit of normal; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FEF25%-75%, forced midexpiratory flow; ns, not significant. ***P<0.001.

weight, oligohydramnios, diagnosis of BPD or severe BPD, duration of respiratory support, and duration of mechanical ventilation were associated with FEV₁/FVC below the LLN. However, differences in the diagnosis of BPD or severe BPD were insignificant after controlling for gestational age, birth weight, and sex. Moreover, only oligohydramnios (odds ratio [OR], 3.54) and longer duration of mechanical ventilation (OR, 1.03) were associated with FEV₁/FVC below the LLN

Table 3. Perinatal factors associated with FEV1/FVC results

(Table 3). The result of the quantile regression analysis of the perinatal factors associated with the chest CT score is presented in Table 4. Oligohydramnios (median difference, 2.54) and longer duration of mechanical ventilation (median difference, 0.04) were significantly associated with higher chest CT scores according to multivariate regression, but not with the diagnosis of BPD or severe BPD.

| Variable | >LLN (n=82) | <lln (n="68)" th="" –<=""><th colspan="2">Univariate analysis</th><th colspan="2">Multiple logistic regression</th></lln> | Univariate analysis | | Multiple logistic regression | |
|---|-------------------|---|---------------------|---------|------------------------------|---------|
| | | | OR (95% CI) | P value | OR (95% CI) | P value |
| GA (wk) | 29.3 (27.9–30.6) | 28.1 (26.6–29.8) | 0.79 (0.67–0.93) | 0.005 | 0.90 (0.62–1.31) | 0.896 |
| Bwt (g) | 1.215 (999–1.531) | 1.003 (841–1,307) | 0.99 (0.99–1.00) | 0.006 | 1.00 (0.99–1.01) | 0.825 |
| Female sex | 37 (45.1) | 29 (42.6) | 0.90 (0.47–1.73) | 0.761 | 0.61 (0.25–1.49) | 0.613 |
| SGA | 9 (11.0) | 12 (17.6) | 1.74 (0.69–4.41) | 0.241 | 1.92 (0.40–9.36) | 0.418 |
| Antenatal steroids | 33 (40.2) | 32 (47.1) | 1.37 (0.71–2.64) | 0.347 | - | - |
| PIH | 14 (17.1) | 16 (23.5) | 1.50 (0.67–3.36) | 0.320 | - | - |
| Chorioamnionitis | 14 (17.1) | 17 (25.0) | 1.73 (0.77–3.86) | 0.180 | - | - |
| Oligohydramnios | 4 (4.9) | 11 (16.2) | 4.07 (1.23–13.50) | 0.015 | 3.54 (1.08–11.55) | 0.036 |
| PROM | 30 (36.6) | 25 (36.8) | 1.13 (0.57–2.22) | 0.732 | - | - |
| Diagnosis of BPD | 58 (70.7) | 59 (86.7) | 2.71 (1.16–6.33) | 0.021 | - | - |
| Diagnosis of severe BPD | 17 (20.7) | 26 (38.2) | 2.37 (1.15–4.88) | 0.018 | 0.92 (0.34–2.51) | 0.866 |
| Use of systemic steroids | 9 (11.0) | 15 (22.1) | 2.31 (0.94–5.68) | 0.064 | - | - |
| Total duration of respiratory support ^{a)} (day) | 42 (21–73) | 69 (47–87) | 1.02 (1.01–1.03) | 0.002 | - | - |
| Duration of MV (day) | 11 (3–27.5) | 26 (8-47) | 1.03 (1.01–1.04) | 0.001 | 1.03 (1.00–1.05) | 0.047 |
| PDA-treated | 29 (35.4) | 25 (36.8) | 1.06 (0.54–2.08) | 0.859 | - | - |

Values are presented as median (interquartile range) or number (%).

FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; LLN, lower limit of normal; CI, confidence interval; GA, gestational age; Bwt, birth weight; SGA, small for gestational age; PIH, pregnancy-induced hypertension; PROM, premature rupture of membranes; BPD, bronchopulmonary dysplasia; MV, mechanical ventilation; PDA, patent ductus arteriosus.

^{a)}Sum of mechanical ventilation, noninvasive ventilation, and supplemental oxygen durations.

Boldface indicates a statistically significant difference with P<0.05.

Table 4. Perinatal factors associated with chest computed tomography score

| | Univariate analysis | | Quantile (median) regression | |
|---|------------------------|---------|------------------------------|---------|
| Variable | Median (95% CI) | P value | Median (95% CI) | P value |
| GA (wk) | -0.77 (-1.17 to 0.377) | <0.001 | 0.11 (-0.58 to 0.79) | 0.760 |
| Bwt (g) | -0.00 (-0.01 to 0.00) | <0.001 | -0.00 (-0.01 to 0.00) | 0.071 |
| Female sex | 0.00 (-2.12 to 2.12) | 1.000 | 0.54 (-0.97 to 2.05) | 0.483 |
| SGA | 1.00 (-2.02 to 4.02) | 0.514 | 1.30 (-1.22 to 3.81) | 0.309 |
| Antenatal steroids | -2.00 (-3.78 to 0.23) | 0.028 | -0.13 (-1.58 to 1.33) | 0.864 |
| PIH | 0.00 (-2.63 to 2.63) | 1.000 | - | |
| Chorioamnionitis | -3.00 (-5.58 to 0.42) | 0.023 | 1.18 (-0.77 to 3.11) | 0.233 |
| Oligohydramnios | -5.000 (-8.31 to 1.69) | 0.003 | 2.54 (0.20 to 4.89) | 0.034 |
| PROM | 0.00 (-1.81 to 1.81) | 1.000 | - | |
| Diagnosis of BPD | 3.00 (1.33-4.67) | <0.001 | - | |
| Diagnosis of severe BPD | 4.00 (2.00-6.00) | <0.001 | 1.22 (-0.93 to 3.36) | 0.264 |
| Use of systemic steroids | 3.00 (0.04-5.96) | 0.047 | -0.10(-3.16 to 1.17) | 0.365 |
| Total duration of respiratory support ^{a)} (day) | 0.05 (0.038-0.07) | <0.001 | - | |
| Duration of MV (day) | 0.07 (0.04-0.10) | <0.001 | 0.04 (0.00-0.08) | 0.044 |
| PDA-treated | -1.00 (-3.23 to 1.23) | 0.377 | - | |

Values were analyzed for 135 of 150 patients (90%) in the FEV1/FVC >LLN and <LLN groups.

FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; LLN, lower limit of normal; CI, confidence interval; GA, gestational age; Bwt, birth weight; SGA, small for gestational age; PIH, pregnancy-induced hypertension; PROM, premature rupture of membranes; BPD, bronchopulmonary dysplasia; MV, mechanical ventilation; PDA, patent ductus arteriosus.

^{a)}Sum of mechanical ventilation, noninvasive ventilation, and supplemental oxygen durations.

Boldface indicates a statistically significant difference with *P*<0.05.

Discussion

To our knowledge, this is the first study to investigate objective pulmonary functional and structural changes in preterm children using a longitudinal cohort in Korea. This study demonstrated that school-aged children with severe BPD had significantly impaired pulmonary function in terms of FEV₁/FVC and FEF_{25%-75%} compared with those with moderate or non/mild BPD. The median z score or %pred of FEV₁ and FVC in the severe BPD group were lower than those of the non/mild and moderate BPD groups; however, they still fell within the normal range. Chest CT showed structural lung abnormalities in the severe BPD group. The presence of abnormalities on chest CT was also significantly higher in the severe BPD group than the non/mild BPD group in asymptomatic patients. However, after adjusting for multiple perinatal factors, severe BPD was not independently associated with poor pulmonary function. Prenatal oligohydramnios and a longer duration of ventilator care were strongly associated with a risk of FEV₁/FVC below the LLN, and a higher chest CT score.

Data from previous cohort studies of pulmonary function in preterm-born children showed impaired lung function at 8-12 years of age, mainly in the form of airflow obstruction (decreased FEV₁), which was seen in children with BPD and, to a lesser degree, in children without BPD. Levin et al.⁷) explained that this obstructive pattern suggests dysanaptic or differential growth of the airways and lung parenchyma. Naravanan et al.¹⁵⁾ reported lower z-FEV₁ in preterm infants born at <32 weeks of gestation, more dominantly in those with BPD, and similar alveolarization in preterm and term infants through a helium-3 magnetic resonance scan study. Our data also demonstrated an obstructive pattern of pulmonary function, although the FEV₁ trend was relatively normal, and the FEV₁/FVC was significantly reduced, demonstrating the airflow limitation is the main pathophysiology of these population.

Notably, impaired pulmonary function was found even in asymptomatic patients. Among patients without subjective respiratory symptoms, 36% and 30% had FEV₁/FVC and FEF_{25%-75%} below the LLN, respectively. Moreover, one-third of the patients with non/mild BPD had FEV₁/FVC and FEF_{25%-75%} below the LLN. These findings indicate the presence of significantly impaired pulmonary function, even in preterm children without oxygen dependency at a postmenstrual age of 36 weeks and in asymptomatic preterm-born children.

Arroyas et al.¹⁶⁾ reported that preterm birth at <32 weeks of gestation was an independent risk factor for asthma in adolescence. In the present study, asthma was diagnosed more frequently in the severe BPD group than in the other groups. However, the proportion of participants with BDR \geq 12% and allergic sensitization did not differ among the groups. This can be attributed to a fixed or structural component (dysanpasis) of BPD, although the obstructive component of BPD may also be due to airway inflammation and smooth muscle hypertrophy, which are responsive to standard asthma management.¹⁷

Structural analysis of preterm-born children has been performed in a few single-center cohort studies. One study from Australia showed parenchymal structural changes using chest CT at age 9–11 years; these resulted from significant abnormalities in 92% of children born at ≤32 weeks of gestation.¹⁸⁾ In the same study, air trapping observed on CT scans was associated with an early gestational age and increased continuous positive airway pressure duration. However, lung volumes were generally not different between preterm children with and without BPD. Extensive remodeling of the lungs leads to changes in lung architecture with regional heterogeneity, showing features such as lung hyperinflation and abnormal parenchymal lesions.¹⁹⁾ Our data showed that the semi-quantitative chest CT score correlated with BPD severity and low pulmonary function (FEV₁, FEV₁/FVC, and FEF_{25%-75%}).

BPD is often defined as a developmental disorder, with its pathogenesis being linked to underdeveloped lungs, inflammation, barotrauma or volutrauma due to mechanical ventilation, and oxidative stress due to respiratory treatment of immature lungs.²⁰⁾ The lungs of prematurity survivors with and without BPD show abnormal parenchymal and vascular growth, with frequent respiratory infections in the first 2 years of life.²¹⁾ In addition, some of these patients fail to reach optimal peak lung function in early adulthood. Furthermore, many studies have shown abnormalities in lung function and structures in patients with BPD; these persist throughout childhood, adolescence, and young adulthood in patients with BPD.¹⁹⁾ Moreover, studies have shown mixed results regarding whether children with a history of very low birth weight and BPD exhibited any difference in lung function compared with those with a history of very low birth weight without BPD.³⁾ However, as these studies used different criteria for gestational age and birth weight and different definitions of BPD, it is difficult to compare the results. Reportedly, 20%-25% of patients with chronic obstructive pulmonary disease (COPD) have never smoked.^{22,23)} Early life events are also associated with the development of chronic airway obstruction.²⁴⁾ Notably, few longitudinal studies have been conducted after early adulthood; however, preterm infants may be at an increased risk of developing COPD later in life.²⁵⁾

According to our multivariate analysis, oligohydramnios and duration of ventilator care, but not BPD, were independently associated with both low lung function and abnormal structure. This is consistent with the conclusions of other recent large-scale studies. Hart et al.²⁶⁾ suggested that gestational age and intrauterine growth restriction, but not BPD, were significantly associated with poor lung function in preterm-born children aged 7–12 years. Developmental restriction of alveolar and vascular structures *in utero* and further insults after birth might be the underlying pathogeneses of chronic lung disease in preterm infants. These results also disprove that traditional BPD diagnostic criteria cannot predict long-term respiratory prognosis directly.

New etiologies for COPD were recently proposed, and COPD due to abnormal lung development was reclassified as COPD-D (COPD due to abnormal lung development was reclassified as COPD-D).²⁷⁾ Through longitudinal follow-ups of preterm-born children through adulthood, functional and structural changes will be serially monitored, allowing individualized therapeutic or preventive strategies for impaired lung function to be provided. In addition, we plan to explore early prediction models for risk stratification in preterm infants by combining perinatal and environmental data related to pulmonary function with imaging data from a larger number of participants. Furthermore, assessing more recent patients is essential when evaluating the longterm outcomes of the recently introduced ventilator strategy (noninvasive ventilator care from early life) and enhanced general supportive care of preterm infants.

Our study has some limitations. First, children whose caregivers were concerned about their respiratory health may have been more likely to participate in the study. This may have led to a selection bias, particularly among asymptomatic individuals. Second, some patients with severely declining respiratory function may have been less likely to be included in our study cohort because we excluded children who could not undergo PFTs owing to neurologic impairment. However, patients with severe BPD had significantly lower body weight for their age at the time of PFT compared with those om the other 2 groups; therefore, there is possibility that being underweight may have influenced the PFT results. Third, we used the internationally accepted GLI scores as the standard reference for our cohort instead of a control group. Finally, the extent of the chest CT findings is likely to be limited by the insensitivity of the scoring method because it does not account for multiple presentations within the same lobe, as observed in previous studies.

In conclusion, preterm-born children, especially those with severe BPD, are at a high risk of pulmonary functional and structural abnormalities at school age. Of note, oligohydramnios and the duration of mechanical ventilation after birth can be prenatal and postnatal independent risk factors for low lung function and abnormal structure, respectively. Therefore, longitudinal follow-ups and screening for lung function and adequate interventions are warranted in preterm infants, including those who are asymptomatic.

Footnotes

Supplementary materials: Supplementary Tables 1-3 and Fig. 1 can be found via https://doi.org/10.3345/cep.2023.01053.

Conflicts of interest: No potential conflict of interest relevant to this article was reported.

Funding: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean Government (MSIT) (NRF-2018R1A5A2025079, NRF-2022R1F1A1074624), the Severance Hospital Research Fund for Clinical Excellence (SHRC) (C-2020-0014), a grant from the Severance Children's Hospital (C-2021-0024), and the Ilsung Research Award of Korean Academy Pediatric Allergy and Respiratory Disease (2019).

Acknowledgments: We thank the preterm-born children and families for participating in the study and providing informed consent. We also thank all the healthcare workers in NICUs at Severance Children's Hospital and Gangnam Severance Children's Hospital.

Author contribution: Conceptualization:SJE, KKW, JJE; Formal Analysis: SJE, HJ, JH; Investigation: LSM, EHS, KSY, LJ; Methodology: LMJ, SJE; Project Administration: JJY, KKW; Writing-Original Draft: SJE; Writing-Review & Editing: JJY, KKW, PMS, SMH

ORCID:

Jeong Eun Shin [®] https://orcid.org/0000-0002-4376-8541 Soon Min Lee [®] https://orcid.org/0000-0003-0174-1065 Mi-Jung Lee [®] https://orcid.org/0000-0003-3244-9171 Jungho Han [®] https://orcid.org/0000-0001-6661-8129 Joohee Lim [®] https://orcid.org/0000-0003-4376-6607 Haerin Jang [®] https://orcid.org/0000-0003-3237-2813 Ho Seon Eun [®] https://orcid.org/0000-0001-7212-0341 Min Soo Park [®] https://orcid.org/0000-0002-4395-9938 Soo Yeon Kim [®] https://orcid.org/0000-0003-4965-6193 Myung Hyun Sohn [®] https://orcid.org/0000-0003-1589-4142 Kyung Won Kim [®] https://orcid.org/0000-0003-4529-6135

REFERENCES

- 1. Chawanpaiboon S, Vogel JP, Moller AB, Lumbiganon P, Petzold M, Hogan D, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. Lancet Glob Health 2019;7:e37-46.
- Kim SY. Changes in neonatal outcomes in Korea. J Korean Med Assoc 2016;59:498-505.
- 3. Islam JY, Keller RL, Aschner JL, Hartert TV, Moore PE. Under-

standing the short- and long-term respiratory outcomes of prematurity and bronchopulmonary dysplasia. Am J Respir Crit Care Med 2015;192:134-56.

- 4. Lum S, Kirkby J, Welsh L, Marlow N, Hennessy E, Stocks J. Nature and severity of lung function abnormalities in extremely pre-term children at 11 years of age. Eur Respir J 2011;37:1199-207.
- Di Filippo P, Giannini C, Attanasi M, Dodi G, Scaparrotta A, Petrosino MI, et al. Pulmonary outcomes in children born extremely and very preterm at 11 years of age. Front Pediatr 2021;9:635503.
- Fortuna M, Carraro S, Temporin E, Berardi M, Zanconato S, Salvadori S, et al. Mid-childhood lung function in a cohort of children with "new bronchopulmonary dysplasia." Pediatr Pulmonol 2016;51:1057-64.
- Levin JC, Sheils CA, Gaffin JM, Hersh CP, Rhein LM, Hayden LP. Lung function trajectories in children with post-prematurity respiratory disease: identifying risk factors for abnormal growth. Respir Res 2021;22:143.
- Simpson SJ, Hall GL, Wilson AC. Lung function following very preterm birth in the era of 'new' bronchopulmonary dysplasia. Respirology 2015;20:535-40.
- 9. Shin JE, Jang H, Han JH, Park J, Kim SY, Kim YH, et al. Association between bronchopulmonary dysplasia and early respiratory morbidity in children with respiratory distress syndrome: a case–control study using nationwide data. Sci Rep 2022;12:7578.
- 10. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723-9.
- 11. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38.
- Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-87.
- 13. Quanjer PH, Brazzale DJ, Boros PW, Pretto JJ. Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry. Eur Respir J 2013;42:1046-54.
- 14. Shin SM, Kim WS, Cheon JE, Kim HS, Lee W, Jung AY, et al. Bronchopulmonary dysplasia: new high resolution computed tomography scoring system and correlation between the high resolution computed tomography score and clinical severity. Korean J Radiol 2013;14:350-60.
- Narayanan M, Beardsmore CS, Owers-Bradley J, Dogaru CM, Mada M, Ball I, et al. Catch-up alveolarization in ex-preterm children: evidence from (3)He magnetic resonance. Am J Respir Crit Care Med 2013;187:1104-9.

- Arroyas M, Calvo C, Rueda S, Esquivias M, Gonzalez-Menchen C, Gonzalez-Carrasco E, et al. Asthma prevalence, lung and cardiovascular function in adolescents born preterm. Sci Rep 2020;10:19616.
- 17. Collaco JM, McGrath-Morrow SA. Bronchopulmonary dysplasia as a determinant of respiratory outcomes in adult life. Pediatr Pulmonol 2021;56:3464-71.
- Simpson SJ, Logie KM, O'Dea CA, Banton GL, Murray C, Wilson AC, et al. Altered lung structure and function in midchildhood survivors of very preterm birth. Thorax 2017;72:702-11.
- 19. Thébaud B, Goss KN, Laughon M, Whitsett JA, Abman SH, Steinhorn RH, et al. Bronchopulmonary dysplasia. Nat Rev Dis Primers 2019;5:78.
- 20. Mosca F, Colnaghi M, Fumagalli M. BPD: old and new problems. J Matern Fetal Neonatal Med 2011;24 Suppl 1:80-2.
- 21. Moschino L, Bonadies L, Baraldi E. Lung growth and pulmonary function after prematurity and bronchopulmonary dysplasia. Pediatr Pulmonol 2021;56:3499-508.
- 22. Lamprecht B, McBurnie MA, Vollmer WM, Gudmundsson G, Welte T, Nizankowska-Mogilnicka E, et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 2011;139:752-63.
- 23. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009;374:733-43.
- Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet 2015; 385:899-909.
- 25. Stocks J, Hislop A, Sonnappa S. Early lung development: lifelong effect on respiratory health and disease. Lancet Respir Med 2013;1:728-42.
- Hart K, Cousins M, Watkins WJ, Kotecha SJ, Henderson AJ, Kotecha S. Association of early-life factors with prematurityassociated lung disease: prospective cohort study. Eur Respir J 2022;59:2101766.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the prevention, diagnosis, and management of chronic obstructive pulmonary disease (2023 report) [Internet]. GOLD; 2023 [cited 2023 Jul 31]. Available from: https:// goldcopd.org/2023-gold-report-2/.

How to cite this article: Cheraghi M, Nikouei M, Mansouri M, Hemmatpour S, Moradi Y. Effect of vitamin E supplementation on bilirubin levels in infants with hyperbilirubinemia: a double-blind randomized clinical trial. Clin Exp Pediatr 2024;67:257-66.